Here are the S-1 registration statements from Enveric Biosciences, Inc. (ENVB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences, Inc. has filed an S-1 registering 680,620 shares of common stock underlying January 2026 warrants, including Series G, Series H and placement agent warrants issued in connection with a January 2026 registered direct offering and concurrent private placement.
The filing covers issuance of shares upon warrant exercise and their resale by selling stockholders. Enveric will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $4.16 per share for the Series G and H warrants and $5.5125 per share for the placement agent warrants, planned for product development, working capital and general corporate purposes.
The company focuses on non-hallucinogenic, neuroplastogenic small-molecule therapies, led by EB-003, and highlights significant risks, including substantial liquidity needs, going concern uncertainty, dependence on early-stage drug candidates, future dilution from equity financings and warrants, and high volatility in its Nasdaq-listed ENVB shares.